Next Article in Journal
Oral Microbiome Signatures in Hematological Cancers Reveal Predominance of Actinomyces and Rothia Species
Previous Article in Journal
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg
Open AccessReview

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases

1
Department of Neurology, Hanover Medical School, 30625 Hannover, Germany
2
Department of Neurology, University Hospital Essen, 45147 Essen, Germany
3
Department of Neurology and Experimental Neurology, Charité Universitätsmedizin Berlin and German Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany
4
Department of Rheumatology & Immunology, Hannover Medical School, 30625 Hannover, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(12), 4067; https://doi.org/10.3390/jcm9124067
Received: 31 October 2020 / Revised: 8 December 2020 / Accepted: 15 December 2020 / Published: 16 December 2020
(This article belongs to the Section Infectious Diseases)
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a challenge for all participants in the healthcare system. At the beginning of the pandemic, many physicians asked themselves what risk their patients, especially those with chronic diseases, were exposed to. We present an overview of all patients with multiple sclerosis (MS) and SARS-CoV-2 infection published in the literature so far. In total, there are publications on 873 SARS-CoV-2 positive MS patients and information on the outcome can be given for 700 patients. With regard to the different disease modifying therapies (DMTs), by far the most cases were described under anti-CD20 treatment (n = 317). The mortality rate of all MS patients was 4% and a further 3% required invasive or non-invasive ventilation. When looking at the severe and fatal cases, it is particularly noticeable that patients without DMTs, with previous cardiovascular diseases, or with a severe degree of disability are at risk. Immunosuppressive therapy itself does not appear to be a substantial risk factor. Rather, it is reasonable to assume that the therapies could be protective, either directly, by mitigating the cytokine storm, or indirectly, by reducing the disease activity of MS. View Full-Text
Keywords: SARS-CoV-2 pandemic; COVID-19; multiple sclerosis; disease-modifying therapies SARS-CoV-2 pandemic; COVID-19; multiple sclerosis; disease-modifying therapies
Show Figures

Figure 1

MDPI and ACS Style

Möhn, N.; Konen, F.F.; Pul, R.; Kleinschnitz, C.; Prüss, H.; Witte, T.; Stangel, M.; Skripuletz, T. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. J. Clin. Med. 2020, 9, 4067. https://doi.org/10.3390/jcm9124067

AMA Style

Möhn N, Konen FF, Pul R, Kleinschnitz C, Prüss H, Witte T, Stangel M, Skripuletz T. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases. Journal of Clinical Medicine. 2020; 9(12):4067. https://doi.org/10.3390/jcm9124067

Chicago/Turabian Style

Möhn, Nora; Konen, Franz F.; Pul, Refik; Kleinschnitz, Christoph; Prüss, Harald; Witte, Torsten; Stangel, Martin; Skripuletz, Thomas. 2020. "Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases" J. Clin. Med. 9, no. 12: 4067. https://doi.org/10.3390/jcm9124067

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop